New research reveals that individuals who stop using popular GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who end conventional diet and exercise regimens.
Research printed in a prominent medical journal demonstrates that while overweight people often shed substantial amounts of their total mass while on the medication, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals using these treatments should be aware of the risk of quick weight regain when the medication concludes," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a return to original mass in about 18 months.
Comparing Therapies
The study, which examined 37 of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers point out that people who lose weight through dieting generally have a less rapid creep back—approximately 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Doctors believe the mode of action of the drugs explains the accelerated regain.
These medications mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication means hunger is no longer kept in check, making excessive eating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals say that, considering the significant potential of relapse, the treatment is often ongoing.
This opinion is reinforced by drug manufacturers, who say that the results "highlight the chronic nature of obesity," comparing it to managing diseases like high blood pressure.
Patient Accounts
People who have stopped the medication explain a sudden return of cravings.
"It was like a switch activating and you become ravenous," said one woman.
This challenge is worsened if patients have not developed sustainable dietary or behavioural modifications during therapy.
Growing Adoption
Figures show that millions of people in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is more common among females than males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Finally, clinicians caution that while the jabs are potent agents for shedding pounds, they are not a magic solution and maintained weight loss likely depends on ongoing behavioural support.
